PharmaCyte Biotech, Inc. (PMCB): Total Liabilities
$11.77M
As of 2026-04-30
$6.90M
As of 2026-07-31
+171.8%
3-year compound annual growth
+74.6%
5-year compound annual growth
+33.9%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-04-30 | $11.77M | +259.2% | 2026-07-29, Balance as of period end |
| 2025-04-30 | $3.28M | -83.9% | 2026-07-29, Balance as of period end |
| 2024-04-30 | $20.39M | n/m | 2025-08-11, Balance as of period end |
| 2023-04-30 | $586.6K | -16.7% | 2024-08-13, Balance as of period end |
| 2022-04-30 | $704.4K | -2.8% | 2023-07-31, Balance as of period end |
| 2021-04-30 | $724.8K | -32.7% | 2022-07-28, Balance as of period end |
| 2020-04-30 | $1.08M | +45.1% | 2021-08-10, Balance as of period end |
| 2019-04-30 | $742.9K | +15.3% | 2020-08-13, Balance as of period end |
| 2018-04-30 | $644.2K | +11.0% | 2019-08-13, Balance as of period end |
| 2017-04-30 | $580.2K | -9.0% | 2018-07-20, Balance as of period end |
| 2016-04-30 | $637.6K | -58.1% | 2017-07-27, Balance as of period end |
| 2015-04-30 | $1.52M | +306.9% | 2016-07-29, Balance as of period end |
| 2014-04-30 | $373.7K | -90.2% | 2016-01-19, Balance as of period end |
| 2013-04-30 | $3.80M | +0.3% | 2014-08-04, Balance as of period end |
| 2012-04-30 | $3.79M | +11.7% | 2013-07-29, Balance as of period end |
| 2011-04-30 | $3.39M | n/a | 2012-08-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | $11.77M | +259.2% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $843.57M | -1.6% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $22.92M | -19.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $11.18B | -1.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $633.31M | -34.5% |
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.38B | +22.1% |
Compare PMCB, VXRT, RGEN, CSBR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗